236 related articles for article (PubMed ID: 28747357)
21. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
Amengual JE; Johannet P; Lombardo M; Zullo K; Hoehn D; Bhagat G; Scotto L; Jirau-Serrano X; Radeski D; Heinen J; Jiang H; Cremers S; Zhang Y; Jones S; O'Connor OA
Clin Cancer Res; 2015 Oct; 21(20):4663-75. PubMed ID: 26116270
[TBL] [Abstract][Full Text] [Related]
22. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
[TBL] [Abstract][Full Text] [Related]
23. HDAC6 inhibitor ACY-1215 improves neuropathic pain and its comorbidities in rats of peripheral nerve injury by regulating neuroinflammation.
Chen C; Liu A; Lu Q; Luo L; Li J; Ke J; Liu Y; Feng X
Chem Biol Interact; 2022 Feb; 353():109803. PubMed ID: 34998817
[TBL] [Abstract][Full Text] [Related]
24. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
25. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
26. Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury.
Lin CF; Hsu KC; HuangFu WC; Lin TE; Huang HL; Pan SL
BMC Pharmacol Toxicol; 2020 Mar; 21(1):21. PubMed ID: 32178737
[TBL] [Abstract][Full Text] [Related]
27. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.
Belibi FA; Reif G; Wallace DP; Yamaguchi T; Olsen L; Li H; Helmkamp GM; Grantham JJ
Kidney Int; 2004 Sep; 66(3):964-73. PubMed ID: 15327388
[TBL] [Abstract][Full Text] [Related]
28. In vitro cyst formation of ADPKD cells.
Sharma M; Reif GA; Wallace DP
Methods Cell Biol; 2019; 153():93-111. PubMed ID: 31395386
[TBL] [Abstract][Full Text] [Related]
29. Histone Deacetylase Inhibitors Reduce Cysts by Activating Autophagy in Polycystic Kidney Disease.
Sun L; Hu C; Zhang X
Kidney Dis (Basel); 2019 Jun; 5(3):163-172. PubMed ID: 31259178
[TBL] [Abstract][Full Text] [Related]
30. Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice.
Wang D; Wang B; Liu Y; Dong X; Su Y; Li S
Neurochem Res; 2019 Nov; 44(11):2460-2469. PubMed ID: 31571096
[TBL] [Abstract][Full Text] [Related]
31. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
Jochems J; Boulden J; Lee BG; Blendy JA; Jarpe M; Mazitschek R; Van Duzer JH; Jones S; Berton O
Neuropsychopharmacology; 2014 Jan; 39(2):389-400. PubMed ID: 23954848
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
Tsuji G; Okiyama N; Villarroel VA; Katz SI
J Allergy Clin Immunol; 2015 May; 135(5):1228-39. PubMed ID: 25458911
[TBL] [Abstract][Full Text] [Related]
33. Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).
Nikonova AS; Deneka AY; Kiseleva AA; Korobeynikov V; Gaponova A; Serebriiskii IG; Kopp MC; Hensley HH; Seeger-Nukpezah TN; Somlo S; Proia DA; Golemis EA
FASEB J; 2018 May; 32(5):2735-2746. PubMed ID: 29401581
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Hedgehog signaling suppresses proliferation and microcyst formation of human Autosomal Dominant Polycystic Kidney Disease cells.
Silva LM; Jacobs DT; Allard BA; Fields TA; Sharma M; Wallace DP; Tran PV
Sci Rep; 2018 Mar; 8(1):4985. PubMed ID: 29563577
[TBL] [Abstract][Full Text] [Related]
35. Polycystin-1 dependent regulation of polycystin-2 via GRP94, a member of HSP90 family that resides in the endoplasmic reticulum.
Yao Q; Outeda P; Xu H; Walker R; Basquin D; Qian F; Cebotaru L; Watnick T; Cebotaru V
FASEB J; 2021 Oct; 35(10):e21865. PubMed ID: 34486178
[TBL] [Abstract][Full Text] [Related]
36. Multidrug therapy for polycystic kidney disease: a review and perspective.
Aguiari G; Catizone L; Del Senno L
Am J Nephrol; 2013; 37(2):175-82. PubMed ID: 23428809
[TBL] [Abstract][Full Text] [Related]
37. Dopamine receptor antagonists as potential therapeutic agents for ADPKD.
Paul P; Ramachandran S; Xia S; Unruh JR; Conkright-Fincham J; Li R
PLoS One; 2019; 14(5):e0216220. PubMed ID: 31059522
[TBL] [Abstract][Full Text] [Related]
38. The genetics and physiology of polycystic kidney disease.
Calvet JP; Grantham JJ
Semin Nephrol; 2001 Mar; 21(2):107-23. PubMed ID: 11245774
[TBL] [Abstract][Full Text] [Related]
39. Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease.
Stayner C; Iglesias DM; Goodyer PR; Ellis L; Germino G; Zhou J; Eccles MR
Hum Mol Genet; 2006 Dec; 15(24):3520-8. PubMed ID: 17082250
[TBL] [Abstract][Full Text] [Related]
40. Role of calcium in adult onset polycystic kidney disease.
Yanda MK; Liu Q; Cebotaru V; Guggino WB; Cebotaru L
Cell Signal; 2019 Jan; 53():140-150. PubMed ID: 30296477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
